GoodRx (NASDAQ:GDRX) Price Target Cut to $6.00 by Analysts at KeyCorp

GoodRx (NASDAQ:GDRX) had its target price reduced by KeyCorp from $7.00 to $6.00 in a report published on Wednesday morning,Benzinga reports. They currently have an overweight rating on the stock.

GDRX has been the subject of several other research reports. Barclays dropped their price objective on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. Morgan Stanley lowered their price objective on GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 17th. Mizuho assumed coverage on GoodRx in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 target price for the company. Finally, Citigroup lowered their price target on shares of GoodRx from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Five research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, GoodRx has a consensus rating of “Moderate Buy” and a consensus price target of $8.43.

GoodRx Trading Down 2.9 %

Shares of GDRX stock opened at $4.28 on Wednesday. GoodRx has a fifty-two week low of $4.09 and a fifty-two week high of $9.26. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The stock’s fifty day moving average is $4.79 and its two-hundred day moving average is $6.61. The firm has a market capitalization of $1.63 billion, a P/E ratio of -142.67, a PEG ratio of 3.43 and a beta of 1.27.

Institutional Trading of GoodRx

Hedge funds have recently added to or reduced their stakes in the stock. nVerses Capital LLC acquired a new stake in GoodRx in the third quarter valued at about $33,000. Plato Investment Management Ltd acquired a new stake in shares of GoodRx in the 2nd quarter valued at approximately $43,000. EP Wealth Advisors LLC acquired a new stake in shares of GoodRx in the 3rd quarter valued at approximately $73,000. Sanctuary Advisors LLC purchased a new stake in shares of GoodRx in the third quarter valued at approximately $85,000. Finally, Dark Forest Capital Management LP acquired a new position in GoodRx during the second quarter worth $86,000. 63.77% of the stock is owned by institutional investors and hedge funds.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.